Identification and development of new biopharmaceuticals

Arzneimittel-Forschung/Drug Research

Volumn 48, Issue 5, 1998, Pages 523-430

  Werner, Rolf G ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Biologics; Biopharmaceuticals; Gene therapy; Human genome project; Oligonucleotide antisense therapy; Protein replacement therapy; Second generation molecules

Indexed keywords

ARTICLE; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG SCREENING; GENE THERAPY; GENETIC DISORDER; MEDICAL GENETICS;

ANIMALS; DRUG DESIGN; DRUG INDUSTRY; GENE THERAPY; GENETIC ENGINEERING; HUMANS; RECOMBINANT PROTEINS;

EID: 0031862612     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Filipovich, A. H., Krawczak, C. L., Kersey, J. H. et al., Br. J. Haematol. 60, 143 (1985)
2. Conelly, S., Gardner, J. M., McClelland, A. et al., Human Gene Ther. 7, 183 (1996)
3. Van den Driesche et al., J. Cell Biochem. Suppl. 18A, 236 (1994)
4. Carducci, M. et al., J. Cell. Biochem. Suppl. 18D, 251 (1994)
5. Tripathy, S. et al., J. Cell Biochem. Suppl. 18D, 473 (1994)
6. Descamps, V., Blumenfeld, N., Villeval, J. L. et al., Human Gene Ther. 5, 979 (1994)
7. Descamps, V., Blumenfeld, N., Perricaudet, M. et al., Human Gene Ther. 2, 411 (1995)